Biobank for calciphylaxis research

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Partners Calciphylaxis Biobank aims to enhance understanding of calciphylaxis, a rare vascular calcification disorder, by collecting and storing patient samples. This observational study focuses on identifying the pathophysiology and risk factors associated with calciphylaxis, which currently lacks effective treatment options. By collaborating with the Partners Biobank, the study will utilize existing infrastructure to support patient consent and sample collection, thereby addressing significant gaps in calciphylaxis research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female ≥18 years old
2. Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician
3. Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making

Exclusion Criteria:

1. Patients \<18 years of age
2. Prisoners

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Sagar U Nigwekar, MD, MMSc — Massachusetts General Hospital
• Study coordinator: Sagar U Nigwekar, MD, MMSc
• Email: snigwekar@mgh.harvard.edu
• Phone: 617-726-7872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• Human amniotic-derived mesenchymal stem cell treatment for calciphylaxis

  This will try human amniotic-derived mesenchymal stem cells as a treatment for adults 18–75 who have calciphylaxis, including people with chronic kidney disease whether they are on dialysis or not.

  Recruiting Early Phase 1 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT04592640

• SelfWrap-Assisted Arteriovenous Fistulas for Chronic Kidney Disease

  This study is testing if a new wrap called SelfWrap can make it safer and more effective for people with chronic kidney disease to have a new arteriovenous fistula created.

  Recruiting at 28 sites VenoStent · Bullhead City, Arizona and 27 other locations · NCT06001827

• Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes

  This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07868666

• Ribupatide PK in People with Kidney Impairment

  This study tests how a single shot of ribupatide behaves in the body for people with severe kidney problems compared to those with normal kidney function.

  Recruiting at 2 sites Phase 1 Kailera · Orlando, Florida and 1 other locations · NCT07793929

• Intradiay dialysis exercise to improve posture in adults with end-stage kidney disease

  This study tests whether a 12-week supervised exercise program done during dialysis can improve posture in adults on maintenance hemodialysis.

  Recruiting Pardis Specialized Wellness Institute · Isfahan · NCT07720401

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.